Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitis

(RTTNews) - Galderma (GALD) reported new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Wednesday 30 September →